Tomorrow should prove to be interesting as AMGN will be holding an analyst call at 8 est. They will be giving details regarding the status of numberous trials. The "WHOS WHO" of biotech analysts will be on the call with their typical round of questions. I expect the newest trail for omecamtiv mecarbil
to be part of these discussions. I will be listening to it live and will post anything meaningfull to CYTK.
"Grabbing up the tar-covered rabbit, Brer Fox swung him around and around and then flung him head over heels into the briar patch. Brer Rabbit let out such a scream as he fell that all of Brer Fox's fur stood straight up. Brer Rabbit fell into the briar bushes with a crash and a mighty thump. Then there was silence.
Brer Fox cocked one ear toward the briar patch, listening for whimpers of pain. But he heard nothing. Brer Fox cocked the other ear toward the briar patch, listening for Brer Rabbit's death rattle. He heard nothing. "
Yes, it's true, "omecamtiv mecarbil" rolls off the tongue as sweetly as Tar Baby and I have been drawn in, holding in the briar for ever so long a time. But, maybe,
just maybe, we'll break free.
"Brer Fox hid himself in the bushes near the road and he waited and waited for Brer Rabbit to come along. At long last, he heard someone whistling and chuckling to himself, and he knew that Brer Rabbit was coming up over the hill. As he reached the top, Brer Rabbit spotted the cute little Tar Baby. Brer Rabbit was surprised. He stopped and stared at this strange creature. He had never seen anything like it before! "
Holding a company thru earnings is generally only a concern when they are expected to have earnings. With CYTK, as with many small biotech's, this isn't a worry yet. There has been no material change in the company over the past 3 months other than the recent financing deal. R&D expenses should have remained contstant as well as G&A costs.
Thanks Dr. Coop, Your posts are very informative and appreciated. I'm a little Leary obout holding thru earnings.....they can obviously make news that day...good or bad??Not for the faint of heart...that's for sure.
AMGN's director of R&D is speaking now. Out of 90 ongoing programs he has chosen 7 to talk specifically about. He has already said that they are "very very excited about omecamtiv mecarbil and has saved discussion regarding this program for last.